Astellas Pharma (ALPMF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Astellas Menopause Study in Japan: What Investors Should Know
The study, officially titled “A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms Associated With Menopause,” tests long-term safety in women with hot flashes. It matters because it supports wider use of Astellas Pharma’s non-hormonal menopause drug beyond the U.S. market.
The trial evaluates fezolinetant, an oral non-hormonal drug already approved in the U.S. as VEOZAH™, against a placebo. The goal is to show that daily treatment for up to one year is safe and well tolerated by Japanese women and can offer an alternative to hormone therapy.
This is an interventional Phase 3 study where participants are randomly assigned to either fezolinetant or placebo. It uses a parallel group model and is triple-blinded, meaning patients, doctors, and outcome assessors do not know who gets the active drug, and the main purpose is treatment assessment.
The study started enrolling in early 2024, aligning with Astellas’ push to build post-U.S. approval data. Primary completion occurred within the planned 52-week treatment and follow-up window, and the latest update on April 6, 2026, confirms that the trial status is now completed and data are being consolidated.
For investors, this update reduces regulatory risk around Asian expansion for fezolinetant and supports a longer revenue runway for Astellas Pharma Inc. Positive long-term safety in Japan could strengthen the product’s profile versus hormone therapy and emerging non-hormonal rivals, which may support ALPMF sentiment, though final impact hinges on detailed results and payer uptake.
The study is now completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about ALPMF’s potential, visit the Astellas Pharma drug pipeline page.